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EFFECTIVENESS OF INTERMITTENT FASTING ON BIOCHEMICAL
AND ANTHROPOMETRIC MARKERS IN OBESE ADULTS WITH
CARDIOVASCULAR RISK. A SYSTEMATIC REVIEW
EFECTIVIDAD DEL AYUNO INTERMITENTE SOBRE MARCADORES BIOQUÍMICOS Y ANTROPOMÉTRICOS
EN ADULTOS OBESOS. UNA REVISIÓN SISTEMÁTICA
Francisca Osses-Carrasco1,a, Francisca Gómez-Zúñiga1,a, Miguel Ángel López-Espinoza1,b

ABSTRACT
Introduction: Obesity is a problem present in almost all societies, which has led to the search for diﬀerent
methods to combat it. One of them is intermittent fasting (IF), characterized by periods without eating (16 to 24
hours), limited or no caloric intake, combined with normal eating windows. Objective: To determine the
eﬀectiveness of intermittent fasting on biochemical and anthropometric markers in obese adults. Methods: A
systematic review was proposed that postulated to study blinded or open clinical trials of IA interventions,
compared with a control group. The response variables were: systolic and diastolic blood pressure, total
cholesterol, LDL, HDL and triglycerides, blood glucose, fat mass, weight, waist circumference, BMI and heart
rate. The search and identi cation of studies was masked. The risks of bias for the Cochrane collaboration were
assessed. They underwent meta-analysis (random eﬀect), with R 4.0.0. Results: Six studies were included,
involving 10-48 weeks of intervention with alternate-day fasting and time-restricted feeding, reporting some
statistically signi cant changes for diﬀerent variables. Conclusion: Intermittent fasting could intervene in the
reduction of cardiovascular risk due to improvement in BMI and biochemical parameters.
Keywords: Intermittent fasting; Obesity; Systematic review; Lipid metabolism; Body composition; Blood
pressure. (Source: MESH-NLM)

RESUMEN
Introducción: La obesidad es un problema presente en casi todas las sociedades, lo que ha conllevado a buscar
distintos métodos para combatirla. Uno de ellos es el ayuno intermitente (AI), caracterizado por periodos sin
ingesta (16 a 24 hr), ingesta calórica limitada o nula, combinada con ventanas de alimentación normal.
Objetivo: Determinar la efectividad del ayuno intermitente sobre los marcadores bioquímicos y
antropométricos en adultos obesos. Métodos: Se planteó una revisión sistemática que postuló estudiar
ensayos clínicos enmascarados o abiertos de intervenciones de AI, comparado con grupo control. Las variables
de respuesta fueron: presión arterial sistólica y diastólica, colesterol total, LDL, HDL y triglicéridos, glicemia,
masa grasa, peso, circunferencia de cintura, IMC y frecuencia cardiaca. La búsqueda e identi cación de los
estudios fue enmascarada. Se evaluaron los riesgos de sesgo de la colaboración Cochrane. Se sometieron a
meta-análisis (efecto aleatorio), con R 4.0.0. Resultados: Se incluyeron 6 estudios, de 10-48 semanas de
intervención con ayuno en días alternos y alimentación con restricción de tiempo, reportándose algunos
cambios estadísticamente signi cativos para distintas variables (especi car). Conclusión: El ayuno
intermitente podría intervenir en la disminución del riesgo cardiovascular por mejoría en IMC y parámetros
bioquímicos.
Palabras claves: Ayuno intermitente; Obesidad; Revisión sistemática; Metabolismo lipídico; Composición
corporal; Presión arterial. (Fuente: DeCS- BIREME)
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INTRODUCTION

body weight, and having positive eﬀects on glycemic

Worldwide, during the last two decades, obesity has
been considered a global public health problem (1,2) . It is
characterized by an increase in body fat, with a BMI
equal to or greater than 30 kg/m2 (3) , associated with
multiple well-described factors such as Socioeconomic
level (4) , Years of education(5) , Obesogenic environments
(6)
., Food quality (1) , Culture (1) , Race (7) , Sex (3) , Genetics (8) ,
Sleep disturbance (9) , Drug use (10,11) , Stress (12) , Hormonal
changes (4) , Eating in front of screens (13) , and Sedentary
lifestyle(14) .

control due to the decrease in insulin levels

Obesity is a frequent problem in countries with
diﬀerent realities. According to the Organization for
Economic Cooperation and Development (OECD) in
2017 (15.16) the following countries stand out: United
States (40%), Chile (34.4%), Mexico (33.3%), New
Zealand (32 .2%), Hungary (30%), Turkey (28.8%),
Portugal (28.7%), Canada (28.1%) and Australia (27.9%).
Body weight is controlled by multiple organs,
hormones, and metabolic pathways, as well as
environmental factors. The Energy Balance Model
(EBM) and high-calorie-dense processed foods explain
the increase in fat (17). A series of comorbidities such as
arterial hypertension, insulin resistance, and diabetes,
hypercholesterolemia, among others, are observed (18) .

(24)

,

according to studies with animals and humans (20) . Even
though it may be a potentially interesting future dietary
strategy for longevity (23) , its study is incipient and the
long-term eﬀect of this nutritional strategy is not clear.
There fo re, our s t u d y a i ms to d e ter m i n e t h e
eﬀectiveness of intermittent fasting on biochemical
and anthropometric markers in obese adults.

METHODS
Systematic review design
A systematic review of clinical trials based on Preferred
Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA)(25) .

Study Eligibility Criteria
Randomized clinical trials were collected (simple or by
balanced blocks), that have hidden the randomization
sequence, with or without blinding. The patients of
both sexes who were studied are in an age range
between 18 to 65 years, with obesity (BMI ≥ 30 kg/m2),
and patients with cardiovascular comorbidities (for

The basis of obesity management is the control of
energy balance by reducing intake and increasing
energy expenditure (19) .To this, it has been added other
types of approaches such as intermittent fasting diets,
eating patterns where the individual spends a period of
time with little or no energy intake, versus intermediate
periods of normal food intake (20) . There are variants such
as complete fasting on alternate days: food intake on 1
day and then fasting the next day (21) ; alternate day
fasting: consumption of 20-25% of total energy
expenditure on fasting days (22) ; time-restricted eating:
meals with a certain energy value during the “food
window”(20) ; and nally, religious fasting(23) . According to
Johnstone (24) , intermittent fasting is considered to be
less restrictive compared to traditional methods of
calorie restriction. The most popular and used variation
is 16:8, that is, a 16-hour fast and an 8-hour nutritional
window(23) .
This type of strategy allows positive changes in patients
with obesity and comorbidities, maintaining average
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example metabolic syndrome) were also accepted. The
interventions that were studied are: Alternate-day
Fasting (ADF): consumption of 20 to 25% of total energy
expenditure on scheduled fasting days, and normal
feeding for 24 hr; time-restricted eating: fasting for a
certain time, with a feeding window. The control group
should be characterized by the consumption of a usual
diet. The Intervention time was at least 10 weeks.

The following response variables were considered:
systolic and diastolic blood pressure (mmHg), total
cholesterol, LDL, HDL, triglycerides, blood glucose
(mg/dl), BMI (kg/m2), percentage body fat mass, weight
(kg), waist circumference (cm), and heart rate (bpm). In
the case of the unit of measure of the biochemical
indicators previously indicated described with mmol/L,
they were transformed with conversion factors (26) .
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Search strategy

intervention characteristics; control group; main

Search strategies were developed between June and

results. The CONSORT guideline

July 2021. The keywords that were used were extracted

facilitate critical reading and extraction of the required

from Medical Subject Heading (Mesh) and non-

information.

(27)

was applied to

controlled words obtained from the speci c language
of the topic were added to them.

Measurement quality
Each researcher individually evaluated the ve risks of

The following databases were used: Pubmed, Cochrane
L i b r a r y, a n d Pro q u e s t . I n a d d i t i o n , t h e s i t e
Clinicaltrials.org was reviewed to nd out the status of
any unpublished clinical trial. No publication date or
language restrictions were applied.

bias according to the domains suggested by the
Cochrane Collaboration (28) . Each reviewer rated one of
the following 3 alternatives for each risk of bias: “low”,
“high” or “unclear”. Once the results were opened, the
degree of concordance of the responses was evaluated
and in case of disagreement, a third researcher

Selection of studies

collaborated to reach a consensus response. For this

Two previously masked and trained reviewers identi ed
work, the Rev. Manager 5.3 program(29) was applied.
whether the titles of the clinical trials contained
information associated with the research question and

Statistic analysis
eligibility criteria. Each of the reviewers classi ed the
clinical trials as: “included”, “excluded” and “uncertain”.
Once the results were opened, potential
inconsistencies were evaluated and resolved by
consensus with a third reviewer. Then, the available
articles were subjected to full reading by the same two
previously masked reviewers, to classify studies as

Clinical trials with homogeneity underwent metaanalysis to obtain weighted mean diﬀerences, with
their respective 95% con dence intervals. The randomeﬀects method was applied (intra- and inter-study
variability are assumed). The degree of heterogeneity
was measured with I2 and Cochran's Q test, with p <

“included” or “excluded”. Disagreements were resolved

0.10. The Metafor package (30) was applied in R, version

by consensus with a third reviewer.

4.0.0.(31) .

Data extraction

RESULTS

The same two previously identi ed reviewers, in a

Search for results

masked manner, extracted from the included articles:

The search process for the articles included is presented

author and

in Figure 1.

year of

publication;

population;
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Included

Screening

Identiﬁcation

Identiﬁcation of studies via databases and registers
Identiﬁed records 4124 from:
Databases (n = 4098)
PubMed: 1692
Cochrane library: 1876
Proquest:530
Registers (n =26)
Clinicaltrials.org: 26

Removed records before
screening: (2412)
Duplicate removed records (n
= 23)
Records marked as ineligible
by automation tools (n = 2389)
Records removed for other
reasons (n = 0)

Screened records
(n = 1712)

Excluded records
(n = 1693)

Reports sought for retrieval
(n = 19)

Reports not retrieved
(n = 0)

Reports assessed for eligibility
(n = 19)

Excluded Reports: 13
Include overweight subjects (n
= 6)
Does not meet the age range (n
= 3)
Does not comply with the
intervention time (n = 2)
Unﬁnished studies (n = 1)
Compilation Study (n=1)

Studies included in review
(n = 6)
Reports of included studies
(n = 0)

Figure 1. Flow chart of included studies (32)
Six studies published on or before 2021 were included
and used for description in the qualitative phase. A
meta-analysis of two studies included in this systematic
review was performed (34,36) .

) interventions, in which subjects consumed 25% of
their initial energy needs on the fasting day (24 hr) and
ate ad libitum on each alternate feeding day within 24
hr. One study included a time-restricted fasting (TRF)

Characteristics of included studies

intervention, where subjects consumed food within a

The main characteristics of the included studies are
available in Table 1. Five studies were conducted in the
US (33, 34, 36 – 38) and one study in Brazil (35) . The
number of participants ranged from 16 to 83
participants, the mean ages ranged from 25 to 65 years,
and the proportion of female participants ranged from
75% to 88%(35-35) , except for one study that included only
women(36) .

12-hour period, then fasted for the other 12 hours. All
the studies presented two groups, except for one study
that had 3 interventions and 1 control (37) . All studies
evaluated weight, BMI, and fat mass (33-38) , ve studies
evaluated blood pressure (33,35-38) , six studies evaluated
LDL (33,34,36-38) , four studies evaluated heart rate (33,35,37,38) ,
four studies evaluated waist circumference (34,35,37,38) , ve
studies evaluated total cholesterol and triglycerides

The interventions lasted between 10 and 48 weeks. Five
of the studies included alternate day fasting (ADF)
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(33,34,35-38)

, four studies evaluated HDL (33,36-38) , and only one

study evaluated glucose(37) .
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K,

S,

Hoddy
2014

Bhutani
2010

First
author,
year

A randomized
controlled trial.

A randomized
controlled trial
using
a
strati ed
sample.

Design

Chicago, E.E.U.U.

women 75% y men 25%.

Intervention group Women 45 ±
3 years old / Men 46 ± 5 years
old.

Sample of 16 obese subjects,
intervention group 45 to 51
years old.

Chicago, E.E.U.U.

ADF-D: 19 participants, 45 ± 3
years.

ADF SM: 20 participants, 46 ± 2
years.

ADF-L: 20 participants; 45 ± 3
years.

Sample of 74 obese subjects,
aged between 25 and 65 years.

Study population

All subjects consumed 25% of their
initial energy requirements on the
fasting day and ate ad libitum on the
feeding day.

Self-selected ADF feeding phase:
subjects underwent a 4-week selfselected ADF feeding period, but their
feeding was not administered.

ADF controlled feeding phase: Each
subject participated in a 4-week ADF
controlled feeding period, where their
feeding was administered.

Alternate day fasting (ADF):

1) ADF-lunch (ADF-L), 2) ADF-dinner
(ADF-D), o 3) ADF-small meal (ADF-SM)

All subjects consumed 25% of their
initial energy requirements on the
fasting day (24 h) and ate ad libitum on
each alternate feeding day (24 h).

Alternate day fasting (ADF):

Intervention

Table 1. Characteristics of included studies.

Initial 2-week control
phase, each subject was
required to maintain
their body weight stable
by maintaining their
usual eating and activity
habits.

Each
subject
who
participated in a 2-week
baseline period was
asked to maintain stable
body
weight
and
continue their usual diet.

Control

10 weeks

10 weeks

Intervention
duration

López-Espinoza et al.: Effectiveness of intermittent fasting on biochemical and anthropo
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A randomized
controlled trial.

K,

S,

Varady
2009

Bhutani
2013

A parallel-arm
randomized
controlled trial.

A randomized
controlled trial.

De Oliveira I,
2021

ADF intervention: 25
participants; 42 ± 2 years old.

Sample of 83 obese participants,
age between 25 to 65 years old.

Chicago, E.E.U.U

Age between 35 65 years old.

Sample of 16 obese subjects, 12
women and 4 men, the same
used in the control and
intervention.

Maceió-Alagoas, Brasil.

Intervention age: 31.80 ± 6.96
years old.

Control age: 31.03 ± 7.16 years
old.

women 100%.

Sample of 56 obese women, age
between 19 to 44 years in both
groups.

Combination group and ADF group: 4week controlled feeding period (they
consumed 25% of their initial energy
requirements on the "fasting day" and

4-Week Weight Loss/ADF SelfSelected Food Intake Phase: Subjects
still consumed 25% of their baseline
energy requirements on the fasting
day and consumed food ad libitum on
the day of feeding. However, during
this period, no food was provided to
the subjects.

4-week weight loss phase / ADF
controlled food intake phase: All
subjects consumed 25% of their
baseline energy requirements on the
"fast" day (24 h) and then consumed
food ad libitum on each alternate
"feed" day (24 h), providing food to the
subjects.

Alternate day fasting (ADF):

Time-restricted
fasting
(TRF)
Hypoenergetic diet (with a de cit of
500 - 1000 kcal of energy expenditure).
HCO: 45-55%; Lip: 25-30% Prot: 1525%. Time restriction for the feeding
period. 12-hour fast and 12-hour
feeding window.

Subjects in the control
and exercise groups were
asked to maintain their
usual eating habits and

Subjects were asked to
maintain stable body
weight by maintaining
their usual eating and
exercise habits for 2
weeks. As such, each
subject served as their
own control.

Hypoenergetic diet (with
a de cit of 500-1000 kcal
of energy expenditure)
HCO: 45-55%; Lip: 2530% Prot: 15-25%.

12 weeks

10 weeks

48 weeks

Revista de la Facultad de Medicina Humana, Vol. 22 [2021], Iss. 4, Art. 18
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A randomized
controlled trial.

Chicago, E.E.U.U

The same macronutrient composition
was used.

All subjects consumed 25% of their
energy requirements on the fasting
day (24-hour period) and 125% of their
energy requirements on the feeding
day (24-hour period).

ADF HF: 15 participants; 42,4 ±
3 years old

ADF LF: 17 participants; 43,2 ±
2,3 years old

For 8 weeks: ADF-HF (100 g total fat) or
ADF-LF (55 g total fat) intervention.

Sample of 32 obese participants,
between 25-65 years old.

The same macronutrient
composition was used.

For 2 weeks, each subject
participated in an initial
2-week
weight
maintenance period in
which they consumed
either the HF (100 g total
fat) or LF (55 g total fat)
diet, providing 100% of
their
energy
requirements.

alimentary or dietary
advice. Subjects in the
control and exercise
group consumed an ad
libitum amount of food
each day.

were not provided with
any

10 weeks

Abbreviations: ADF, alternate day fasting; ADF-L, alternate day fasting-lunch; ADF-D, alternate day fasting-dinner; ADF-SM, alternate day fasting-small meals;
ADF-HF, alternate day fasting-high fat; ADF-LF, alternate day fasting-low fat.

Klempel M,
2012

Chicago, E.E.U.U

(they continued the ADF regimen but
no food was provided for the fast day).

8-week self-selected feeding period.

Combined intervention: 18
participants; 45 ± 5 years old.

Control: 16 participants; 49 ± 2
years old.

consumed food ad libitum on each
"feeding day") and a

Exercise intervention: 24
participants; 42 ± 2 years old.

López-Espinoza et al.: Effectiveness of intermittent fasting on biochemical and anthropo
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Risk of bias assessment
The risk of bias assessment is presented in Figure 2.

Figure 2. Risk of bias assessment of the included studies.
Green: low risk of bias; yellow: unclear risk of bias; and red: high risk of bias.

Of the 6 studies included in the SR (see gure 2), 3
studies presented a low risk of selection bias

(33,37,38)

because they reported details of their random

risk, while Bhutani et al.(37) had a high risk of bias, as there
is a large diﬀerence in the number and gender of
participants in each intervention.

sequence generation. Three studies, Bhutani et al., De
Oliveira et al., and Varady et al.(34-36) presented an unclear
risk of selection bias since it does not indicate how the
study participants were selected. All 6 studies did not
clearly state a method of allocation concealment, thus
having an unclear risk of bias.
All studies assessed are at unclear risk of conduct or
performance bias as they do not state whether the
administrator remains masked. Regarding the risk of
Detection bias, all the studies included in this
systematic review have a low risk of bias, although the
study is open, the treatment administrators cannot
interfere in the measurement of the response variable,
because automated instruments were used. Regarding
attrition or follow-up bias, ve studies presented a low
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In reporting bias, all studies were at low risk of bias, as
signi cant study ndings were reported.

Results of included studies
The main results of the included studies are
summarized in Table 2. Of the 6 papers used in the
systematic review, statistically signi cant diﬀerences
were found in weight loss and BMI (Table 2-A) at the end
of the interventions, in the case of Hoddy et al. (33) ,
Bhutani et al. (34) , Varady et al. (36) , Klempel et al. (38) with 10
weeks of intervention and Bhutani et al. (37) with 12
weeks of intervention, reducing body weight in a range
of 3 to 6 kg and BMI in a range of approximately 1 to 3
kg/m2. However, De Oliveira et al. (35) did not present
signi cant changes after 48 weeks of intervention in
both variables.

8

Hoddy
2014

First
author,
year

K,

(kg/m )
Eﬀect size (pre-post):
ADF-L: 1.3±0.2
(P <0,050)
ADF-D: 1.4±0.2
(P <0,050)
ADF-SM: 1.5±0.2
(P <0,050)

(kg)

Eﬀect size (pre-post):

ADF–L: 3,5±0,4

(P <0,001)

ADF–D: 4,1±0,5

(P <0,001)

ADF–SM: 4,0±0,5

(P <0,001)

2

BMI

Weight

Published by INICIB-URP, 2021
(P=0,070)
ADF – SM:
Pre:119±3
Post: 112±3

ADF–SM:
Pre:110±7
Post:110±7
(P= 0,790)

(P=0,600)

Post: 79±1

Pre: 83±1

ADF – SM:

(P=0,150)

Post: 76±1

Pre: 79±2

ADF – D:

(P=0,560)

Post: 76±2

Pre:78±2

ADF – L:

DBP:

(P=0,040)

Post: 112±2

(P= 0,980)

Pre:117±3

Post: 119±8

(P <0,001)

ADF – D:

(P=0,570)

Pre:120±6

Post: 112±3

ADF – D:

Pre:115±3

ADF – L:

SBP:

(mmHg)

BP

(P=0,540)

Post: 113±9

Pre:114±11

ADF – L:

(mg/dl)

LDL

(weekly)

ADF-SM: 0,135±0,032

(P <0,001)

ADF-D: 0,135±0,042

(P <0,001)

ADF-L: 0,075±0,027

Eﬀect size (pre-post):

Fat mass (kg)

Table 2A. . Results of included studies (continue).

(mg/dl)

Glucose

López-Espinoza et al.: Effectiveness of intermittent fasting on biochemical and anthropo
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Varady
2009

K,

De Oliveira
I, 2021

Bhutani S,
2010
Post: 32,8±0,9
(P <0,050)
SFI (day 70)
Post: 31,4±0.9
(P <0,050)
HD:
Pre: 33,12±3,63
Post:
77,53
83,07]

Post: 93,7±5

(P <0,050)

SFI (day 70)

Post: 90,8±4,8

(P <0,050)

HD:

Pre: 80,25±9,4

Post:

77,53 CI95%
83,07]

Post:

Post:
87,33
CI95%
[76,81; 97,84]*

(P <0,001)

Post: 72±8
(P <0,010)

SFI-ADF:
Post: 29,9±2,1
(P <0,010)

SFI-ADF:

Post: 73±9

CFI-ADF:

Pre: 102±9

(P <0,050)

Post: 72±8

SFI (day 70)

(P <0,050)

Post: 73±9

CFI (day 42)

Pre: 106±10

(P <0,001)

(P <0,010)

Post: 32,8±1,0

SFI – ADF: 0,68±0,1
(week)

5,4 ± 0,8 kg

CFI-ADF:

CFI – ADF: 0,67±0,1
(week)

CI95%

Eﬀect size (post – pre):

(P=0,020)

Post:
46,21
[42,69;49,74]*

Pre: 44,41±5,47%

HD+TRF:

Pre: 33,7±1,0

(P=0,840)

[76,81;

[71,99;

Post: 44,24 CI95% [41,13;
47,35]

Pre: 43,55±4,7%

HD:

(P <0,050)

Post: 38,1±1,8

SFI (day 70)

(P <0,050)

Post: 41,3±2,7

CFI (day 42)

Pre: 43±2,2

Eﬀect size (pre-post):

(P=0,960)

Pre: 33,53±4,53

Pre: 81,25±13,51

87,33
CI95%
97,84]*

HD+TRF:

HD+TRF:

CI95%

CFI (day 42)

CFI (day 42):

[71,99;

Pre: 33,7±1

Pre: 96±5,3 kg

size

Post:

SFI-ADF:
78,8±2,5
NS

Post:

ADF:

ADF:

(pre-

CFI-ADF:
79,2±2,1

Pre: 80,3 ± 2,7

DBP:

(P <0,050)

SFI
–
5,1±1,6%

CFI
–
4,4±1,8%

SBP:

Eﬀect
post):

(P=0,460)

Post: 83,8 CI95%
[79,55;88,05]*

Pre: 86,2±13,2

HD+TRF:

Post: 82,29 CI95%
[78,05;86,54]

Pre: 86,51±10,08

HD:

DBP:

(P=0,480)

Post: 122,41 CI95%
[116,49;128,34]*

Pre: 127,1±15,29

HD+TRF:

Post: 119,44 CI95%
[115,47;123,41]

Pre:124,03±11,28

HD:

SBP:
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Bhutani S,
2013

Combination:
91±6
Post: 85±6

Pre:

Combination: Pre: 35±1

Combination: Pre: 45±2

Combination:

SBP:

Post: 33±1

Post: 40±2

Pre: 125±9

(p<0,001)

(p<0,001)

Post: 109±11

Combination: Pre:
113±3

(p<0,001)

(p=0,043)
ADF:

ADF:
Pre: 94±3
Post: 91±3

Pre: 35±1
Post: 34±1
(p<0,001)

(p<0,001)

ADF:
Pre: 43±2
Post: 41±2

ADF:
Pre: 113±8
Post: 112±9

(p=0,008)

(p=0,917)

Exercise:

Exercise:

Combinatio
n:
Pre: 94±2

Post: 111±3

Post: 92±3

(p=0,262)

(p=0,589)

ADF:

ADF:

Pre: 124±3

Pre: 98±5

Post: 120±3

Post: 95±5

(p=0,007)

(p=0,146)

Exercise:

Exercise:

Pre: 113±2

Pre: 92±2

Post: 115±3

Post: 91±2

(p=0,284)

(p=0,862)

Control:

Control:

Pre: 122±5

Pre: 109±7

Post: 129±6

Post: 111±6

(p=0,603)

(p=0,637)

Exercise:
Exercise:
Pre: 93±2
Post: 92±2

Pre: 93±2
Post: 34±1
(p=0,030)

(p=0,027)

Pre: 46±2

Pre: 113±5

Post: 45±2

Post: 113±7

(p=0,182)

(p=0,947)

Control:

Control:

Control:
Control:
Pre: 93±5
Post: 93±5

Pre: 93±5
Post: 35±1
(p=0,707)

(p=0,577)

Pre: 43±4
Post: 43±4
(p=0,570)

Pre: 119±6
Post: 123±8
(p=0,586)

DBP:
Combination: Pre:
76±2
Post: 76±2
(p=0,939)

ADF:
Pre: 82±2
Post: 80±2
(p=0,034)
Exercise:
Pre: 71±2
Post: 76±2
(p=0,976)
Control:
Pre: 76±3
Post: 84±4
(p=0,480)
Klempel M,
2012

Eﬀect size (pre-post):

Eﬀect size (pre-post):

ADF-HF:

ADF-HF:

SBP:

ADF-HF: 4.3 ± 1.0

ADF-HF: 1,7 ± 0,4

Pre: 43,7±1,9

Pre: 119±10

ADF-HF:

ADF-LF: 3.7 ± 0,7

ADF-LF: 1,5 ± 0,3

Post: 38,3±1,8

Post: 90 ± 7

Pre: 111±2

(P <0,0001)

(P <0,0001)
ADF-LF:

ADF-LF:

Pre: 43,6±1,8

Pre: 124±6

ADF-LF:

Post:39,4±39,4

Post: 85 ± 7

Pre: 116±3

(P <0,0001)

(P <0,0001)

Post: 118±3

Post: 109±2

NS

DBP:
ADF-HF:
Pre: 77±3
Post: 75±2

ADF-LF:
Pre: 75±2
Post: 81±3
NS
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Post: 138±8
(P <0,050)

Post: 105±3
(P <0,050)

(P=0,820)

(P=0,800)

SFI (day 70):

Post: 181±7

Post: 72±3

SFI (day 70):

Pre:185±8

Pre: 72±3

(P <0,050)

ADF – SM:

ADF – SM:

(P <0,050)

(P=0,190)

(P=0,050)

Post: 140±7

Post: 190±8

Post: 68±2

Post: 106±3

Pre: 199±8

Pre: 71±2

CFI (day 42)

ADF – D:

ADF – D:

CFI (day 42)

(P=0,920)

(P<0,001)

Pre: 175 ± 8

Post: 184±9

Post: 64±2

Pre: 109±2

Pre: 190±11

Pre: 69±3

(mg/dl)
ADF – L:

(cm)

(bpm)

TC

ADF – L:

WC

HR

Table 2B. Results of included studies (continue).

(P <0,050)

Post: 88±15

SFI (day 70):

(P <0,050)

Post: 110±17

CFI (day 42)

Pre: 136±17

(P=0,910)

Post: 84±9

Pre: 94±9

ADF – SM:

(P=0,100)

Post: 101±12

Pre: 108±14

ADF – D:

(P=0,380)

Post: 96±14

Pre: 104±15

ADF – L:

(mg/dl)

TG

(P=0,690)

Post: 55±3

Pre: 57±3

ADF – SM:

(P=0,700)

Post: 54±3

Pre: 57±4

ADF – D:

(P=0,220)

Post: 52±3

Pre: 55±3

ADF – L:

(mg/dl)

HDL
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(P=0,100)

(P=0,110)

Pre: 71±2

Exercise:

(p=0,711)

Post: 75±2

Pre: 75±2

ADF:

(p=0,384)

Post: 76±2

Combination:
78±2

Pre:

It does not report the
values, but it does
report the trend in a
ﬁgure.
SFI-ADF:

Post: 88±15
(P <0,010)

SFI-ADF:
Post: 138±8
(P <0,001)

Post: 95±2

Pre: 98±2

Exercise:

(p<0,001)

Post: 95±2

Pre: 100±2

ADF:

(p<0,001)

Pre: 181±6

Exercise:

(p=0,053)

Post: 183±11

Pre: 171±8

ADF:

(p=0,658)

Post: 186±12

Pre: 74±6

Exercise:

(p=0,341)

Post: 86±8

Pre: 81±7

ADF:

(p=0,161)

Post: 87±8

Pre: 77±7

Combination:

Post: 110±17

CFI-ADF:

CFI-ADF:
Post: 140±7

Pre: 125±15

Pre: 175±8

Pre: 190±10

Post: 103,84 CI95%
[95,32; 112,36]*

Post: 74,35 CI95%
[71,79;76,91]*

Post: 88±1

Pre: 102,79±3,27

Pre: 76,27±8,79

Combination:

HD+TRF:

HD+TRF:

Combination: Pre: 91±2

Post:
97,07
[91,15; 102,98]

Post: 73,74 CI95%
[69,62;77,85]

Signiﬁcantly reduced
(P < 0.050)

Pre: 98,86±9,61

Pre: 71,85±9,48
CI95%

HD:

HD:

Pre: 51±2

Exercise:

(p=0,807)

Post: 49±3

Pre: 49±2

ADF:

(p=0,041)

Post: 59±4

Pre: 50±3

Combination:

NS

Post: 46±3

SFI-ADF:

Post: 45±4

CFI-ADF:

Pre: 48±4
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Pre: 99±3
Post: 97±2
(p=0,640)

Control:

Pre: 76±3

Post: 77±3

ADF-HF:

ADF-HF:
Pre: 98±1,8
Post: 91±1
ADF-LF:
Pre: 98,8±2.1
Post: 91,5±2.1
(P <0,001)

ADF-HF:

Pre: 75±3

Post: 77 ± 3

ADF-LF:

Pre: 76±3

Post: 73 ± 2

NS

(P <0,0001)

Post: 162±7

Pre: 201±6

ADF-LF:

Post: 172±9

Pre: 206±11

(p=0,784)

(p=0,763)

Post: 187±10

Pre: 185±7

(P <0,001)

Post: 83±10

Pre: 108±13

ADF-LF:

Post: 108±15

Pre: 125±17

ADF-HF:

(p=0,452)

Post: 102±11

Pre: 97±13

Control:

(p=0,290)

Post: 79±5

NS

Post: 83±10

Pre: 60±4

ADF-LF:

Post: 108±15

Pre: 63±5

ADF-HF:

(p=0,166)

Post: 56±3

Pre: 52±3

Control:

(p=0,457)

Post: 52±3

All data ± SEM. *95% conﬁdence interval.

abbreviations: ADF-L, alternate day fasting-lunch; ADF-D, alternate day fasting-dinner; ADF-SM, alternate day fasting-small meals; BMI, body
mass index; LDL, low-density lipoprotein; BP, blood pressure; HR, heart rate; WC, waist circumference; TG, triglycerides; CFI, controlled food
intake; SFI, self-selected food intake; BFP: body fat percentage; SBP; systolic blood pressure; DBP: diastolic blood pressure; bpm, beats per
minute.

Klempel M,
2012

(p=0,921)

Control:

(p=0,925)
Control:

Post: 181±8

(p<0,001)

Post: 71±2
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In the 6 included studies (33-38) , statistically signi cant

Regarding heart rate (Table 2-A), it was analyzed in 5

diﬀerences were found for the variable of fat mass

studies, presenting a signi cant diﬀerence in the study

(Table 2-A), with a duration of interventions ranging

by Varady et al.(36) , and Hoddy et al.(33) . Both studies were

from 10 to 48 weeks, decreasing approximately 1.3 to

developed in a time of 10 weeks. The latter only showed

5.4 kg.

a signi cant diﬀerence in ADF-L (fasting on alternate
days at lunch), marking a diﬀerence between pre and

In the case of the waist circumference variable (Table 2-

post-study of 6 beats per minute, but not for ADF-D and

B), the studies showed that there is a signi cant

ADF-SM.

diﬀerence in the studies by Bhutani et al. (34) , Klempel et
al.(38) , and Bhutani et al.(37) , with a range of 10 to 12 weeks
of intervention and a decrease of 4 to 7 cm. The case of
De Oliveira et al. (35) did not present signi cant changes
for this variable.

Of the 6 included studies, signi cant diﬀerences in SBP
were only found in the study by Varady et al.(36) , in which
it was signi cantly reduced after completing the phase
of controlled and self-selected food intake, during 10
weeks of intervention (Table 2-A).

Regarding the lipid pro le (Table 2-B), signi cant
changes were observed for total cholesterol, LDL

Results of meta-analyses
cholesterol, and triglycerides in the studies by Bhutani
et al.(34) , Varady et al.(36) , and Klempel et al.(38) , which have
a duration of 10 weeks. On the other hand, Hoddy et al.
(33)

, and Bhutani et al. (37) , did not present statistically

signi cant changes in interventions of 10 and 12 weeks,
respectively. De Oliveira et al. (38) do not present results

Only 2 studies were available (34,36) about ve variables:
BMI, fat mass, total cholesterol, LDL cholesterol, and
triglycerides. Both trials have the same intervention
time of 10 weeks. Alternate day fasting was found to
cause a signi cant change in BMI (WMD = -3.93, 95% CI 5.01, -2.85 kg/m2). Regarding the eﬀect sizes of

for these variables.

intermittent fasting on fat mass, in the same two studies
Only 4 studies evaluated HDL cholesterol (Table 2-B),

(34,36)

, with the same intervention time, statistically

Hoddy et al.(33) , Varady et al.(36) , Bhutani 20 et al. 13(37) , and

signi cant observed mean eﬀect sizes were found

Klempel et al.

, of which, they did not present

(WMD = -5.12, 95 % CI -6.16, -4.08 kg). Regarding the

signi cant changes for the variable, varying between 10

lipid pro le, for total cholesterol, a WMD = -37,00 (CI

and 12 weeks of intervention. De Oliveira et al.(35) did not

95%: -40,91; -33,01 mg/dl), and for LDL a WMD = -31,88

present results. The glucose variable was only studied

(CI 95%: -36,17; -27,58 mg/dl). For triglycerides, the

by Bhutani et al. (37) , with 12 weeks of intervention in

change was also statistically signi cant. (WMD = -42,32,

which no statistically signi cant diﬀerence was

CI 95%: -53,09; -31,55 mg/dl). Details are available in

generated (Table 2-A).

Table 3.

(38)
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16
16
32
16
16
32

Masa grasa Buthani 2010
(kg)
Varady 2009
WMD *

Buthani 2010
Varady 2009
WMD *

Buthani 2010
Varady 2009
WMD *

Buthani 2010
Varady 2009
WMD *

c-LDL
(mg/dl)

c-Total
(mg/dl)

Triglicéridos
(mg/dl)

16
16
32

16
16
32

16
16
32

16
16
32

16
16
32

Control
sample

48,37
51,63
100,00

48,37
51,63
100,00

46,94
52,06
100,00

55,94
44,06
100,00

9,50
90,50
100,00

Weight
(%)

-48,00
-37,00
-42,32

-48,00
-37,00
-37,00

-34,00
-30,00
-31,88

-4,90
-5,40
-5,12

-5,20
-3,80
-3,93

Mean
diﬀerence

-6,29; -3,51
-6,97; -3,83
-6,16; -4,08

-8,71; -16,9
-4,94; -2,66
-5,01; -2,85

CI 95%

-59,09; -36,91
-47,39; -26,61
-53,09; -31,55

-59,09; -36,91
-47,39; -26,61
-40,91; -33,01

-40,27; -27,73
-35,90; -24,10
-36,17; -27,58

Abbreviations: WMD, weighted mean diﬀerence; REML, Restricted Estimator Maximum-Likelihood

*Calculated using the REML method

16
16
32

16
16
32

16
16
32

Buthani 2010
Varady 2009
WMD *

IMC (kg/m2)

Intervention: Alternate Day Fasting (ADF)

Response
Variable

Table 3. Meta-analysis results

50,31

0

0

0

0

I2

2,0125

0

0,8290

0,2185

0,5536

Q

0,1560

1,000

0,3626

0,6402

0,4569

P-value

Heterogeneity
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The weight variable could not be subjected to meta-

nutritionist, re ected in the anthropometric and

analysis because the comparison results are diﬀerent,

biochemical results of the clinical trial. The study

expressing the results in diﬀerent ways, where Buthani
et al.(34) express the initial and nal weight of the study in
total kg, whereas Varady et al. (36) present weight change

showed that by not having a strictly controlled
environment, it did not cause adherence and
maintenance of weight loss throughout the study in the
participants.

in kg/week, so the authors of this study decided not to
include it.

In the case of fat mass in ADF interventions, our
systematic review presents a positive change in the

DISCUSSION
The results of our systematic review and meta-analysis

studies, with a decrease in kg (33,34,36-38) , and is consistent
with the meta-analysis carried out, and also for waist
circumference (WC) (34,37,38). These data suggest that the

aimed to determine the eﬀectiveness of intermittent

weight loss observed with ADF is due to a decrease in fat

fasting on biochemical and anthropometric markers in

mass and not fat-free mass

obese adults with cardiovascular risk, in an age range of

metabolic rate, which allows for a greater capacity for

18 to 65 years. In this context, for the weight and BMI
variables, we found favorable changes in intermittent
fasting interventions on alternate days (ADF) (33,34,36-38) ,

(34)

, decreasing the resting

energy utilization(37) .
For the variables total cholesterol, LDL, and TG, there
was a decrease in these variables with ADF (34,36,38) , which

between 10 and 12 weeks. The applied meta-analyses

had an intervention time of 10 weeks, as stated in the

raised a statistically signi cant diﬀerence. This can be

meta-analysis carried out. Circulating free fatty acid

explained by the use of fat mass as an energy substrate

(FFA) oxidation increases during periods of weight loss,

in the fasting period, since normally the energy
substrate used by the tissues corresponds to

while FFA synthesis decreases (39,40) . A relationship is also
observed between the increase in adiponectin
concentrations and the decrease in LDL cholesterol and

carbohydrates, provided through food or reserves. Due

TG levels after treatment, where it is suggested that

to the depletion of these deposits, the metabolic routes

adiponectin can decrease the supply of FFA to the liver

towards lipolysis are derived, with the obtaining of free

for gluconeogenesis, thus decreasing the synthesis of

fatty acids as an energy source and the decrease in
metabolic energy expenditure as a result of

TG. This decrease results in attenuated VLDL secretion,
which in turn would decrease plasma LDL cholesterol
concentrations(40) .

physiological fasting, in this way the body weight
decreases, and therefore the BMI. However, the study of

For the variable HDL, there were no changes in the

De Oliveira et al. (35) published an experience with time-

studies (33,36-38) . Evidence suggests that HDL cholesterol

restricted feeding (TRF), with a duration of 48 weeks,

may require more than 16 weeks to make a change(38) , as

where there were no diﬀerences at the end of the

concentrations generally increase with exercise
depending on intensity, thus requiring a controlled

intervention. This may be due to the prolonged time of

environment under supervision when combining ADF

the study, where the adherence of the participants is

with exercise (41,42) . For this reason, it cannot be

diminished during the months without follow-up by a

categorically con rmed that an increase occurs
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following an intermittent fasting protocol. More

qualitative evidence of our review. Furthermore, the

research should be done in this regard in future studies

study by Davey et al.(50) shows that the number of studies

(43)

.

eligible for meta-analyses is usually very small for all
medical areas, outcomes, and interventions covered by

Heart rate was analyzed in ve studies, showing a
decrease in beats per minute in only two (33,36) . This may
be caused by reduced markers of systemic
in ammation and oxidative stress associated with
atherosclerosis, increasing heart rate variability by
improving parasympathetic tone

(44)

, although as

described in other studies the

ndings are also

Cochrane reviews. Due to the above, it is possible to
consider opening other designs, as well as replicating
this search for the next ve years to evaluate if there are
more clinical trials that meet the criteria and enter the
second version of this SR.

somewhat surprising since ADF does not generally

Intra-study sample size with few participants between

improve heart rate

. Similarly, systolic blood

16 and 83 people is also observed, so the evidence may

pressure only had favorable changes in one study (36).

overestimate the results obtained, however, the studies

This may be caused by weight loss and changes in

included in this systematic review are characterized by

eating habits

. The above parameters improve when

presenting a control in the procedures performed that

the intermittent fasting diet is combined with a physical

require interventions. Therefore, it is recommended to

exercise program in patients with obesity

carry out studies increasing the sample size.

(45,46)

(37,38)

(37,46)

.

From a global standpoint, we can mention that the
variables mentioned above are aﬀected since fasting
induces the coordinated alteration of metabolic and
transcriptional mechanisms. After 12 to 36 hours of
fasting, the human body enters a physiological state of

In the same way, some studies can be observed with an
intervention time of 1 year without achieving favorable
changes, due to poor adherence to treatment, directly
aﬀecting the response variables. The other studies

ketosis characterized by low blood glucose levels,

included an intervention time of 10 to 12 weeks and

decreased liver glycogen deposition, and hepatic

presented better adherence to treatment. Therefore, it

production of ketone bodies

. The production of

is recommended to have constant monitoring during

ketone bodies generates oxidation of fatty acids as an

the intervention time, favoring the adherence of the

energy source, which can be seen re ected in the

participants to obtain positive results.

(48)

decrease in biochemical and anthropometric
parameters (49) .

We found few long-term studies, therefore the longterm results of this type of intervention are unknown.

This study was not without limitations. The

rst

accounts for the small number of studies that we were
able to compile, therefore the evidence is not very
robust to reach a reliable result, however, these studies
are clinical trials that obey the best quality of evidence
available at the time.

However, studies of shorter duration had a positive
impact on the variables. Therefore, the eﬀectiveness of
intermittent fasting for prolonged periods cannot be
veri ed. Our recommendation for possible future
studies is to determine the long-term eﬀectiveness. No
study presented adverse eﬀects in the participants

In the same way, we wanted to meta-analyze in order to

assigned to the comparison groups, therefore, they do

take advantage of the little evidence available and

not report side eﬀects in themselves, which is a lack of

demonstrate a quantitative result, to reinforce the

evidence, limiting the ability to analyze the results. That
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is why we propose to show the adverse eﬀects, to verify
the safety and integrity of the participants in this type of
treatment in future studies.
It was only possible to perform the meta-analysis of 2
studies with a sample size of 16 participants in each one,
so the statistical power is low, although according to
Davey et al. (50) , the minimum number of studies needed
to be eligible for a meta-analysis is two studies and only
two individuals. The studies included in this review are
of high quality and with a moderate to low degree of
heterogeneity, with low variability between studies.
Regardless of the limitations mentioned, it is expected
that in future studies of this nature long-term
interventions will be carried out with a greater number
of participants, increasing adherence to the ADF diet,
hoping for better results. However, the results found are
relevant, since studies of the highest quality were
reviewed, because clinical trials were included, showing
relevant changes in interventions of 10 to 12 weeks,
Authorship contributions: FO-C participated in the
conception of the article, data collection, writing, and
approval of the nal version. FG-Z participated in the
conception of the article, data collection, writing, and
approval of the nal version. ML-E participated in the
conception of the article, statistical data analysis,
writing, and approval of the nal version.

w i t h f avo ra b l e c h a n g e s i n b i o c h e m i c a l a n d
anthropometric parameters. With this systematic
review, we show the current state of research regarding
the eﬃcacy of intermittent fasting in obese patients,
therefore, researchers are encouraged to design more
studies to verify with a higher degree of statistical
power the results concerning the study hypothesis.

CONCLUSIÓN

In conclusion, we can determine that there is evidence
that allows us to think of a favorable relationship
between intermittent fasting and the reduction of
cardiovascular risk in obese patients, as a dietary
therapeutic strategy for a possible nutritional
approach, generating changes in diﬀerent variables
such as weight, BMI, fat mass, lipid pro le, waist
circumference, systolic blood pressure, and heart rate.
Weight loss and the eﬀect produced by fasting could
help reduce fat, improving the lipid pro le of the groups
intervened for a set time, in which, studies with an
intervention time of 10 to 12 weeks showed interesting
changes.
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